A Phase 1 interventional study of MAM01 300 mg SC and MAM01 300 mg IM in Healthy Volunteers, sponsored by Gates Medical Research Institute. Completed at 2 sites in Uganda. Open to participants aged 3 Months to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Gates Medical Research Institute · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Malaria with a site in Uganda — 10 open to participants now, 14 under way, 1 of them phase 3. Malaria · Uganda.
Among the 98 studies in Malaria with a site in Uganda, this one is the 66th largest by enrollment of the 80 interventional ones that give a count, is one of 4 that started in 2025, is one of 5 in phase 1, and was the 87th registered.
1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.
Browse Malaria studies →10 of the 98 studies in Malaria with a site in Uganda are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Uganda, Gabon
Ages 18–65
University of California, San Francisco · Sites in Uganda
Ages up to 17 · Healthy volunteers
Clinton Health Access Initiative Inc. · Sites in Uganda, Burkina Faso
Ages 5 mo–5 yrs
University of North Carolina, Chapel Hill · Sites in Uganda
Healthy volunteers
Yale University · Sites in Uganda
Ages 5–17 · Healthy volunteers
A study can be open while its sites in Uganda have not opened yet or have stopped. Only those recruiting at a site in Uganda →
Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.
This study: 3 Months to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 27 · Phase 4 15
First in 2003; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 125 is below the median of 252 across 939 interventional studies indexed under Malaria.
Median enrollment 458 across the 80 interventional studies, 758 across the 18 observational. Of the 72 that completed or were terminated, 17 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 98 have an industry lead sponsor. The 10 most frequent:
Gates Medical Research Institute is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Gates Medical Research Institute has 2 studies filed under Malaria — fewer than ten, so there is no comparison to draw.
3 of the studies in Malaria with a site in Uganda that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04978272Phase 3Grant Dorsey, M.D, Ph.D.Modifying Immunity in Children With DihydROartemisinin-Piperaquine (MIC-DroP) | 2027-05-05 |
| NCT07749911Clinton Health Access Initiative Inc.Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT) | 2027-06 |
| NCT07545681GlaxoSmithKlineA Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria | 2027-10-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 98 studies in Malaria with a site in Uganda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will test a new drug (MAM01) to find which doses are safe and could help prevent people from getting malaria for at least 4 months. The study will take place in parts of Africa where malaria is common. Part A is an open-label study conducted in healthy adults whereas Part B is double-blind study conducted in young children and infants. Both the parts will evaluate the safety, tolerability and pharmacokinetics of MAM01.
This is a Phase 1b, age de-escalation/dose escalation trial that will be conducted in a setting of perennial Plasmodium falciparum (malaria parasite) transmission in Africa. The study will be conducted in 2 parts: Part A (Dose Escalation in Adults); Part B (Age De-escalation/Dose Escalation in Younger Children and infants).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
PART A
PART B
Exclusion Criteria:
PART A \& PART B
Within 48 hours prior to randomization, acute febrile illness
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive MAM01.
Drug: MAM01 300 mg SC
Participants will receive MAM01.
Drug: MAM01 300 mg IM
Participants will receive MAM01.
Drug: MAM01 2000 mg IV
Participants will be randomized in 3:1 ratio (MAM01 : PBO)
Drug: MAM01 190 mg SC · Drug: Placebo SC
Participants will be randomized in 3:1 ratio (MAM01 : PBO)
Drug: MAM01 225 mg SC · Drug: Placebo SC
Participants will be randomized in 3:1 ratio (MAM01 : PBO)
Drug: MAM01 150 mg SC · Drug: Placebo SC
Participants will be randomized in 3:1 ratio (MAM01 : PBO)
Drug: MAM01 150 mg IM · Drug: Placebo IM
Participants will be randomized in 3:1 ratio (MAM01 : PBO)
Drug: MAM01 150 mg IV · Drug: Placebo IV
Participants will be randomized in 3:1 ratio (MAM01 : PBO)
Drug: MAM01 150 mg SC · Drug: Placebo SC
Participants will be randomized in 3:1 ratio (MAM01 : PBO)
Drug: MAM01 150 mg IM · Drug: Placebo IM
Participants will be randomized in 3:1 ratio (MAM01: PBO)
Drug: MAM01 150 mg IV · Drug: Placebo IV
MAM01 300 mg will be administered SC
MAM01 300 mg will be administered IM route
MAM01 2000 mg will be administered IV
MAM01 190 mg will be administered SC
MAM01 225 mg will be administered SC
MAM01 150 mg will be administered SC
MAM01 150 mg will be administered IM
MAM01 150 mg will be administered IV
Placebo will be administered SC
Placebo will be administered IV.
Placebo will be administered IM
Number of participants reporting Treatment-emergent adverse events (TEAEs)
Time frame: Up to 28 days post dose (Part A and B)
Number of participants reporting serious adverse events (SAEs), adverse events of special interest (AESI), and AEs leading to discontinuation
Time frame: Up to 182 days post dose
Number of participants reporting solicited systemic AEs and solicited injection site AEs (applicable to IM dosing)
Time frame: Up to 7 days post dose
Number of participants reporting solicited systemic AEs and solicited injection site AEs (applicable to SC dosing)
Time frame: Up to 7 days post dose
Percentage of participants with graded abnormal clinical hematology and chemistry laboratory results
Time frame: Up to 28 days post dose
Maximal observed blood concentration of MAM01 following the first dose (Cmax1)
Capillary blood samples will be collected for the analysis pharmacokinetic parameters. Blood concentrations of MAM01 will be measured using a validated immunoassay.
Time frame: Pre- and post-dose (IV dosing groups only) at Day 1, 4, 7, 14, 28, 56, 84, 112, 140, and 182
Concentration at Day 182 (C182)
Time frame: At Day 182 post first dose
Total Area Under the Concentration Curve (AUC) Day 0 - Day 182
Time frame: From 0 to 182 days post dose
Percentage of participants with antidrug antibodies (ADAs) to MAM01
Time frame: At Days 1, 28, 84, and 182
Plan to share: Yes — All IPD data that underlie the results presented herein
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Within 12 months of the study completion date
Access criteria: Anonymized participant-level data may be shared with external researchers in accordance with trial participants' written and executed informed consent and applicable local regulations. Qualified researchers may submit a request along with a research proposal to Gates MRI for review. A data sharing agreement must be in place before any clinical trial data are shared. Additional restrictions may apply due to contractual obligations or regulatory constraints.
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in May 2026, 14 months.
Of 64 non-industry phase 1 interventional studies under Malaria, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 14 months is close to that.
Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gates Medical Research Institute